The Patent Finder

Mirror Biologics, Inc.

19 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 11, 2026
    The maintenance fee for Automated device for biologic drug distribution (US 10,318,712) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
  • 1 fee due Jan 16, 2027
    The maintenance fee for Methods for handling biological drugs containing living cells (US 10,350,242) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
  • 1 fee due Feb 20, 2027
    The maintenance fee for Cells expressing Th1 characteristics and cytolytic properties (US 10,385,315) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for Th1 vaccination priming for active immunotherapy (US 11,833,173) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
  • 2 fees due Jul 12 to 30, 2027 · next Jul 12

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,865,224Allogeneic cellular immunotherapy for opportunistic infection
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,272,001Ablative immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,320,794Ablative immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,160,852Method of vaccinating using allogeneic cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,972,594Ablative immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,751,372Vaccine compositions and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,744,158Th1 vaccination priming for active immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,695,397Th1 vaccination priming for active immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,233,091Vaccine compositions and methods
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,833,173Th1 vaccination priming for active immunotherapy
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 19 patents shown.
Pro members see all 19.
Pro members: see all 19 patents
Also on record, not counted in the 19: 9 lapsed for an unpaid fee · 18 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 8 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited